| Literature DB >> 33057072 |
Mayumi Ueta1, Hiromi Nishigaki2, Chie Sotozono3, Norihiko Yokoi3, Katsura Mizushima4, Yuji Naito4, Shigeru Kinoshita2.
Abstract
To investigate the role of miRNA in the pathogenesis underlying ocular surface complications in patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) in the chronic stage. Using oligonucleotide microarrays, we performed comprehensive miRNA analysis of the conjunctival epithelium of SJS/TEN patients with severe ocular complications (SOC) in the chronic stage (n = 3). Conjunctival epithelium of patients with conjunctival chalasis (n = 3) served as the control. We confirmed the down- and up-regulation of miRNA of interest by quantitative real-time polymerase chain reaction (RT-PCR) assays using the conjunctival epithelium from 6 SJS/TEN with SOC patients and 7 controls. We focused on miRNA-455-3p, which is significantly upregulated in the conjunctival epithelium of the SJS/TEN patients, and investigated its function by inhibiting miR-455-3p in primary human conjunctival epithelial cells (PHCjEs). Comprehensive miRNA expression analysis showed that the expression of 5 kinds of miRNA was up-regulated more than fivefold, and that the expression of another 5 kinds of miRNA was down-regulated by less than one-fifth. There was a significant difference between the SJS/TEN patients and the controls [analysis of variance (ANOVA) p < 0.05]. Quantitative miRNA PCR assay showed that hsa-miR-31* and hsa-miR-455-3p were significantly up-regulated in the conjunctival epithelium of the SJS/TEN patients. Comprehensive gene expression analysis of PHCjEs transfected with the hsa-miR-455-3p inhibitor and quantitative RT PCR assay showed that ANKRD1, CXCL8, CXCL2, GEM, PTGS2, RNASE8, IL6, and CXCL1 were down-regulated by the hsa-miR-455-3p inhibitor. Quantitative RT-PCR, focused on the genes that tended to be up-regulated in SJS/TEN with SOC, revealed that the expression of IL1A, KPRP, IL36G, PPP1R3C, and ADM was significantly down-regulated in PHCjEs transfected with the hsa-miR-455-3p inhibitor. Our results suggest that miRNA-455-3p could regulate many genes including innate immune related genes in human conjunctival epithelium, and that its up-regulation contributes to the pathogenesis on the ocular surface in SJS/TEN patients with the SOC in the chronic stage. Our findings may lead to the development of new treatments using the miRNA-455-3p inhibitor.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33057072 PMCID: PMC7560850 DOI: 10.1038/s41598-020-74211-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Quantitative miRNA PCR analysis of hsa-miR-455-3p and hsa-miR-31*. Quantification data were normalized to the expression of the internal control, RNU44 RNA. The Y axis shows the increase in specific miRNA over the control samples. Data are the mean ± SEM (controls; n = 7, SJS; n = 6). *p < 0.05.
Figure 2RT-qPCR analysis of PHCjEs transfected with the hsa-miR-455-3p inhibitor. Quantification data were normalized to the expression of the house keeping gene, GAPDH. The Y axis shows the increase in specific mRNA over the control samples. Data are the mean ± SEM (each group n = 4). *p < 0.05.
Results of our previous and present comprehensive gene expression analysis.
| Result of our previous comprehensive gene expression analysis of in vivo human conjunctival epithelium | Result of comprehensive gene expression analysis of PHCjEs with has-miR455-3p inhibitor | Gene symbol | Gene description | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SJS case1_Signal | SJS case2_Signal | Control 1_Signal | Control 2_Signal | SJS_Avg signal (log2) | Control_Avg signal (log2) | Fold change (linear) (SJS vs. control) | inhNC_Signal | inh455_3p_Signal | inh455_3p/inhNC | ||
| 1075.50 | 111.79 | 10.62 | 11.18 | 8.44 | 3.45 | 31.82 | 1302.82 | 637.49 | 0.49 | IL1A | Interleukin 1 alpha |
| 2373.56 | 162.94 | 32.95 | 22.89 | 9.28 | 4.78 | 22.64 | 249.12 | 68.35 | 0.27 | KPRP | Keratinocyte proline-rich protein |
| 2721.25 | 57.38 | 20.30 | 18.10 | 8.63 | 4.26 | 20.61 | 80.22 | 27.45 | 0.34 | IL36G | Interleukin 36, gamma |
| 1255.72 | 1020.35 | 107.04 | 45.95 | 10.14 | 6.13 | 16.14 | 107.44 | 41.33 | 0.38 | PPP1R3C | Protein phosphatase 1, regulatory subunit 3C |
| 1403.14 | 669.83 | 168.58 | 83.44 | 9.92 | 6.89 | 8.17 | 1094.99 | 391.32 | 0.36 | ADM | Adrenomedullin |
| 489.12 | 274.64 | 50.43 | 40.81 | 8.52 | 5.50 | 8.08 | 166.21 | 77.11 | 0.46 | INA | Internexin neuronal intermediate filament protein, alpha |
| 1344.37 | 211.05 | 67.88 | 85.57 | 9.06 | 6.25 | 6.99 | 858.42 | 374.40 | 0.44 | RAET1L | Retinoic acid early transcript 1L |
| 225.85 | 45.91 | 15.49 | 14.67 | 6.67 | 3.91 | 6.76 | 240.41 | 75.71 | 0.31 | DEFB103A | Defensin, beta 103A |
| 2208.05 | 237.62 | 45.91 | 301.61 | 9.50 | 6.88 | 6.16 | 1734.57 | 237.64 | 0.14 | PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
| 229.96 | 237.24 | 38.83 | 45.63 | 7.87 | 5.40 | 5.55 | 50.67 | 24.34 | 0.48 | SERPINB9 | Serpin peptidase inhibitor, clade B (ovalbumin), member 9 |
| 365.23 | 79.63 | 34.36 | 27.58 | 7.41 | 4.94 | 5.54 | 4912.57 | 1291.70 | 0.26 | RNASE7 | Ribonuclease, RNase A family, 7 |
| 842.71 | 566.70 | 137.04 | 134.12 | 9.43 | 7.08 | 5.10 | 421.65 | 75.77 | 0.18 | CTGF | Connective tissue growth factor |
| 144.01 | 60.38 | 15.35 | 22.58 | 6.54 | 4.22 | 5.01 | 745.20 | 156.61 | 0.21 | DKK1 | Dickkopf WNT signaling pathway inhibitor 1 |
| 1516.11 | 196.57 | 136.99 | 87.57 | 9.09 | 6.78 | 4.98 | 186.92 | 51.03 | 0.27 | HSPA2 | Heat shock 70 kDa protein 2 |
| 5220.08 | 3628.07 | 1250.95 | 613.56 | 12.09 | 9.77 | 4.97 | 4999.87 | 1367.19 | 0.27 | SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 |
| 20.02 | 78.70 | 8.46 | 10.11 | 5.31 | 3.21 | 4.29 | 36.94 | 9.93 | 0.27 | TNFAIP6 | Tumor necrosis factor, alpha-induced protein 6 |
| 605.60 | 337.29 | 154.66 | 72.17 | 8.82 | 6.72 | 4.28 | 201.49 | 92.51 | 0.46 | UCA1 | Urothelial cancer associated 1 (non-protein coding) |
| 1749.92 | 92.80 | 165.83 | 62.12 | 8.65 | 6.67 | 3.97 | 1757.02 | 342.16 | 0.19 | NR1D1 | Nuclear receptor subfamily 1, group D, member 1 |
| 159.87 | 63.56 | 20.10 | 32.57 | 6.66 | 4.68 | 3.94 | 640.99 | 135.65 | 0.21 | CCL20 | Chemokine (C–C motif) ligand 20 |
| 56.56 | 29.20 | 11.18 | 10.38 | 5.34 | 3.43 | 3.77 | 160.76 | 67.27 | 0.42 | SNORD114-3 | Small nucleolar RNA, C/D box 114-3 |
| 1168.76 | 398.98 | 186.16 | 186.53 | 9.42 | 7.54 | 3.66 | 114.21 | 46.07 | 0.40 | STX11 | Syntaxin 11 |
| 153.87 | 71.00 | 24.35 | 36.63 | 6.71 | 4.90 | 3.50 | 69.37 | 21.00 | 0.30 | IL20 | Interleukin 20 |
| 274.93 | 122.37 | 35.92 | 79.02 | 7.52 | 5.74 | 3.44 | 86.77 | 37.80 | 0.44 | RND1 | Rho family GTPase 1 |
| 33.18 | 22.38 | 8.45 | 8.06 | 4.77 | 3.04 | 3.30 | 25.99 | 10.65 | 0.41 | THUMPD3-AS1 | THUMPD3 antisense RNA 1 |
| 65.69 | 152.47 | 38.49 | 27.84 | 6.64 | 5.03 | 3.06 | 437.17 | 175.64 | 0.40 | FILIP1L | Filamin A interacting protein 1-like |
Figure 3RT-qPCR analysis of the genes which tend to be up-regulated more than threefold in conjunctival epithelium of SJS/TEN with SOC in our previous comprehensive gene expression analysis, and can be down-regulated less than one-half with transfection of hsa-miR-455-3p inhibitor. Quantification data were normalized to the expression of the house keeping gene, GAPDH. The Y axis shows the increase in specific mRNA over the control samples. Data are the mean ± SEM (each group n = 4). *p < 0.05, **p < 0.005.